- Exact Sciences press release ( NASDAQ: EXAS ): Q2 GAAP EPS of -$0.94 beats by $0.14 .
- Revenue of $521.64M (+20.0% Y/Y) beats by $25.5M .
- The company anticipates revenue of $1.98B - $2.02B during 2022 vs. prior view of $1.985B - $2.032B and consensus of $2.02B.
-
"Exact Sciences' strong second quarter results reflect meaningful progress toward our vision to help eradicate cancer by providing patients better information before diagnosis and throughout their treatment," said Kevin Conroy, chairman and CEO. "We're focusing on getting more people tested with Cologuard ® and Oncotype ® , prioritizing our highest impact projects to reach profitability, and generating high-quality evidence for our pipeline of cancer diagnostic tests."
For further details see:
Exact Sciences GAAP EPS of -$0.94 beats by $0.14, revenue of $521.64M beats by $25.5M